US09058V1035
US09058V1035
BioCryst Pharmaceuticals, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 2.18B EUR | 2.55B EUR | 2.42B EUR | 1.66B EUR |
Enterprise Value | 2.6B EUR | 3.19B EUR | 3.06B EUR | 2.01B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | 6.3x |
Forward P/E | 9.1x | -- | -- | -- |
Price to Sales | 2.32x | 2.71x | 2.73x | 2.28x |
Price to Book | -- | -- | -- | -- |
EV/Revenue | 2.77x | 3.39x | 3.46x | 2.76x |
EV/EBITDA | 6.01x | -- | -- | 5.91x |
Price to FCF (P/FCF) | 6.75x | 6.84x | 7.79x | 4.46x |
EV/FCF | 8.04x | 8.55x | 9.87x | 5.4x |
FCF Yield | 14.81% | 14.63% | 12.83% | 22.42% |